BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$315.55 USD
-12.34 (-3.76%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $315.56 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BIO 315.55 -12.34(-3.76%)
Will BIO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIO
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
National Vision (EYE) Down 6.9% Since Last Earnings Report: Can It Rebound?
BIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now
Bio-Rad (BIO) Faces Low BioPharma Demand, Competitive Pressure
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered
Other News for BIO
Bio-Rad Laboratories: Overvalued Given Current Growth Prospects
Bio-Rad Laboratories Inc (BIO) Stock Price Down 3.84% on Sep 20
Triple-Witch Says, “Remember Me?”
Labroots to Host the 12th Annual Cancer Research & Oncology Virtual Event Series on October 2nd, 2024
UBS highlights 30 stocks poised for potential moves after the Fed’s expected rate cut